Skip to main content

STANDARD BIOTOOLS INC

For the period ended Dec 31, 2023. Filed Mar 1, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 1, 2024

LAB$0.69+9.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

STANDARD BIOTOOLS INC.
Dated: March 1, 2024By:/s/ Michael Egholm, Ph.D.
Michael Egholm, Ph.D.
President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael Egholm and Jeffrey Black, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/Michael Egholm, Ph.D.President and Chief Executive Officer (Principal Executive Officer); DirectorMarch 1, 2024
Michael Egholm, Ph.D.
/s/ Jeffrey BlackChief Financial Officer (Principal Financial and Accounting Officer)March 1, 2024
Jeffrey Black
/s/ Tom CareyChairman of the Board of DirectorsMarch 1, 2024
Tom Carey
/s/ Fenel M. EloiDirectorMarch 1, 2024
Fenel M. Eloi
/s/ Eli CasdinDirectorMarch 1, 2024
Eli Casdin
/s/ Kathy HibbsDirectorMarch 1, 2024
Kathy Hibbs
/s/ Troy CoxDirectorMarch 1, 2024
Troy Cox
/s/ Frank Witney, Ph.D.DirectorMarch 1, 2024
Frank Witney, Ph.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.